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Proposal for the 8th Edition of the AJCC/UICC Staging System
for Nasopharyngeal Cancer in the Era of Intensity-Modulated
Radiotherapy
Jian Ji Pan, MD1,2; Wai Tong Ng, MD3; Jing Feng Zong, MD1,2; Lucy L. K. Chan, BSc3; Brian O’Sullivan, MD4;
Shao Jun Lin, MD1,2; Henry C. K. Sze, FRCR5; Yun Bin Chen, MD6; Horace C. W. Choi, PhD7; Qiao Juan Guo, MD1,2;
Wai Kuen Kan, FRCR8; You Ping Xiao, MD6; Xu Wei, PhD9; Quynh Thu Le, MD10; Christine M. Glastonbury, MBBS11;
A. Dimitrios Colevas, MD12; Randal S. Weber, MD13; Jatin P. Shah, MD14; and Anne W. M. Lee, MD15
BACKGROUND: An accurate staging system is crucial for cancer management. Evaluations for continual suitability and improvement
are needed as staging and treatment methods evolve. METHODS: This was a retrospective study of 1609 patients with nasopharyn-
geal carcinoma investigated by magnetic resonance imaging, staged with the 7th edition of the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) staging system, and irradiated by intensity-modulated radiotherapy at 2 centers in
Hong Kong and mainland China. RESULTS: Among the patients without other T3/T4 involvement, there were no significant differen-
ces in overall survival (OS) between medial pterygoid muscle (MP)6 lateral pterygoid muscle (LP), prevertebral muscle, and para-
pharyngeal space involvement. Patients with extensive soft tissue involvement beyond the aforementioned structures had poor OS
similar to that of patients with intracranial extension and/or cranial nerve palsy. Only 2% of the patients had lymph nodes>6cm
above the supraclavicular fossa (SCF), and their outcomes resembled the outcomes of those with low extension. Replacing SCF with
the lower neck (extension below the caudal border of the cricoid cartilage) did not affect the hazard distinction between different N
categories. With the proposed T and N categories, there were no significant differences in outcome between T4N0-2 and T1-4N3
disease. CONCLUSIONS: After a review by AJCC/UICC preparatory committees, the changes recommended for the 8th edition
include changing MP/LP involvement from T4 to T2, adding prevertebral muscle involvement as T2, replacing SCF with the lower
neck and merging this with a maximum nodal diameter>6cm as N3, and merging T4 and N3 as stage IVA criteria. These changes
will lead not only to a better distinction of hazards between adjacent stages/categories but also to optimal balance in clinical practic-
ability and global applicability. Cancer 2015;000:000–000. VC 2015 American Cancer Society.
KEYWORDS: nasopharyngeal cancer, prognostication, TNM staging system.
INTRODUCTION
An accurate staging system is crucial in cancer management for predicting the prognosis, guiding clinicians in treatment
decisions for different risk groups, and evaluating the results of treatment between centers. The prognostic significance of
a staging system changes with advances in investigation and treatment methods. Evaluations of staging systems to ensure
continual suitability and exploration for further improvement are essential.
It is well recognized that the natural behavior of and therapeutic considerations for nasopharyngeal carcinoma (NPC)
are different from those for other head and neck cancers. A major improvement in the TNM staging system by the American
Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) was the adoption of a customized
system for NPC in the 5th edition.1,2 With data from large retrospective series from Asia, where NPC is most prevalent, the
staging criteria were developed through the merging of the strengths of the 4th edition of the AJCC/UICC system and Ho’s
system.3,4 This was a milestone development that has gained global acceptance as studies from different countries (endemic
and nonendemic) unanimously confirmed substantial improvements in comparison with prior systems.
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No change was recommended in the 6th edition5,6
except for the addition of the term masticator space as a
synonym for infratemporal fossa (one of the T4 criteria)
because, although the intended extent was described in
the staging handbook, the latter was not a clearly defined
space with universal acceptance. In the current 7th edi-
tion,7,8 both terms are retained as T4 criteria; however the
term masticator space now uses the boundaries described
in a classic anatomy textbook instead of the demarcation
used for infratemporal fossa. Additional changes included
downstaging of tumors with extension to the nasal fossa/
oropharynx without parapharyngeal extension (previously
T2a) to T19,10 and a clear definition of retropharyngeal
lymph node involvement (unilateral or bilateral) as N1.11
The management of NPC has undergone substantial
evolution in the past 2 decades. More accurate imaging
methods have allowed better delineation of the tumor extent
and early detection of occult metastases. The transition from
2-dimensional conventional radiotherapy to 3-dimensional
conformal and intensity-modulated radiotherapy (IMRT)
has led to increasing conformity of tumor coverage and spar-
ing of noninvolved structures. The use of combination
chemotherapy has further improved tumor control and cure
rates, especially for advanced locoregional disease. It is, there-
fore, important that the new staging system be based on data
from patients managed with contemporarymethods.12
The preparatory processes for the 8th edition of the
AJCC/UICC staging system included an extensive litera-
ture review and validation of recommendations by con-
temporary series before consensus was attained by
international multidisciplinary experts. Among the sug-
gestions reported in the literature, 4 issues demand serious
consideration: 1) the controversy about the significance of
the masticator space,13-18 2) the uncertainty about the sig-
nificance of prevertebral muscle invasion,19-21 3) the pos-
sibility of replacing the supraclavicular fossa (SCF)3 with
anatomic nodal levels,22-27 and 4) the simplification of
unnecessary subgroups by elimination.27,28
In this study, we evaluated patients who were staged
with magnetic resonance imaging (MRI) and irradiated
with IMRT at 2 hospitals (one in Hong Kong and the
other in Fujian in mainland China) to address these issues
and to develop consensus recommendations by AJCC and
UICC for the coming 8th edition.
MATERIALS AND METHODS
Patients
A total of 1609 consecutive patients with nondisseminated
NPC who were treated at Fujian Provincial Cancer
Hospital and Pamela Youde Nethersole Eastern Hospital
from June 2005 to December 2010 were analyzed (Table
T11). All patients had histological confirmation: 99.2% had
nonkeratinizing (differentiated/undifferentiated) carci-
noma and 0.8% had keratinizing squamous cell carcinoma
according to the World Health Organization classification.
The median age was 47 years (range, 11-84 years); 75%
were male, and 25% were female. The median follow-up
for the whole cohort was 5 years (range, 0.2-9.3 years).
This retrospective study was approved by the respec-
tive local hospitals.
Clinical Staging and Treatment
All patients underwent a complete physical examination,
fiber-optic nasopharyngoscopy, and MRI of the nasopha-
ryngeal and cervical region. An additional metastatic eval-
uation was performed according to institutional polices.
The 7th edition of the AJCC/UICC staging system7,8 was
used for clinical staging at presentation.
All patients were treated with the IMRT technique
with a median total dose of 69.8 Gy (range, 61.6-86.7
Gy). Details of IMRT planning and dose prescription
have been described previously.29,30 Additional treatment
with cisplatin-based chemotherapy (various schedules)
was administered to 92% of patients with stage III disease
and to 73% of patients with stage II disease (Table 1).
Statistical Analysis
The eligibility criteria set for this retrospective study
included histologically confirmed NPC, no gross evidence
TABLE 1. Patient Characteristics
Age, median (range), y 47 (11-84)
Sex, No. (%)
Male 1212 (75)
Female 397 (25)
Performance status, No. (%)
0 1424 (88.5)
1 172 (10.7)
2 11 (0.7)
3 2 (0.1)
Histology, No. (%)
Keratinizing squamous cell 13 (1)
Nonkeratinizing, differentiated 68 (4)
Nonkeratinizing, undifferentiated 1528 (95)
Radiotherapy
Total dose, median (range), Gy 69.75 (61.6-86.7)
Overall treatment time, median (range), d 43 (36-96)
Chemotherapy (cisplatin-based)
Total patients treated, No. (%) 1359 (85)
Sequence, stage II/stage III-IVB,%
Concurrent6 induction/adjuvant 36/56
Adjuvant 2/1
Induction 16/17
Induction1 adjuvant 20/18
Nil 27/8
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of distant metastases, staging with MRI, and irradiation
with radical intent with IMRT. The exclusion criteria
were a history of previous treatment or prior malignancy.
All consecutive eligible patients treated in the 2 participat-
ing centers from June 2005 to December 2010 were
analyzed. The study period was chosen to ensure the most
consistent staging and radiotherapy methods with a
median follow-up of 5 years.
All events were measured from the date of histologi-
cal diagnosis. The primary endpoint for this analysis was
overall survival (OS; time to death due to any cause).
Additional endpoints included distant failure-free survival
(D-FFS; time to distant metastasis), local failure-free sur-
vival according to the T category (L-FFS; time to local
persistence/recurrence), and nodal failure-free survival
according to the N category (N-FFS; time to nodal
persistence/recurrence). The unadjusted actuarial rates
were calculated with the Kaplan-Meier method,31 and the
differences were compared with a log-rank test.32 A Cox
proportional hazards model33 was used to assess the
hazard ratio with a 95% confidence level. Two-sided tests
were used, and those with P values< .05 were considered
statistically significant.
With the current sample size of 1609, the power was
88.5% for detecting a hazard ratio at 1.27 between adja-
cent stages with a 95% confidence level.34 The propor-
tional hazard assumption was also tested. All the Cox
models satisfied the proportional hazard assumption with
P values> .05 for the proportional hazard test.35
The performances of the 7th edition of the AJCC/
UICC staging system and the proposed 8th edition were
also compared with the Akaike information criterion
(AIC)36 and Harrell’s concordance index (c-index).37 Both
the AIC and the c-index were calculated for the Cox pro-
portional hazards regression model and were adjusted for
age and sex. The AIC refers to the information loss of the
selected model; a smaller AIC value suggests a better good-
ness of fit of the model. The c-index measures the ability to
predict the outcomes; a higher c-index suggests a greater
ability to discriminate the outcomes with the model
(ie, better discriminatory power of the model). Internal
validation for the AIC and the c-index was performed
via bootstrapping with 1000 replications. All statistical
analyses were conducted with SPSS 22 and R 3.1.3.
RESULTS
T Category
Among the patients categorized as T4 on the basis of the
current definition of masticator space, those with medial
pterygoid muscle (MP)6 lateral pterygoid muscle (LP)
involvement (n5 590) had a significantly higher rate of
association with other T3/T4 staging criteria in compari-
son with those without MP/LP involvement (n5 1019;
91% vs 44%, P< .001). However, among the patients
without other T3/T4 criteria, the subgroup of patients
with MP/LP involvement (n5 53) had much better OS
than the patients with other T4 criteria (93% vs 71% at 5
years, P5 .003); there were no significant differences in
OS between those with MP/LP involvement, those with
prevertebral muscle involvement, and those with para-
pharyngeal extension alone (Fig. F11A). On the other hand,
the subgroup of patients with extensive soft tissue involve-
ment (infiltration beyond the lateral surface of the LP,
hypopharynx, orbital structures, and parotid gland) but
no other T4 criteria had poor OS similar to that of the
subgroup with intracranial extension and/or cranial nerve
palsy (68% vs 73%, P5 .816; Fig. 1C).
Among the patients with current T3 criteria, there
was no statistically significant difference in OS between
those with involvement of pterygoid structures alone
(medial/lateral pterygoid plate, pterygoid body/process,
pterygomaxillary fissure, and pterygopalatine fossa) and
those with erosion of the skull base and/or cervical verte-
bra (86% vs 79%, P5 .186; Fig. 1B).
Hence, the changes recommended for the 8th edition
include changing the criterion of MP/LP involvement
without other T3/T4 criteria from T4 to T2 and adding
prevertebral muscle involvement as a T2 criterion (Fig. F22A
and Table T22). With the proposed changes, the differences
in L-FFS between T1 and T2 (P5 .048), in D-FFS
between T2 and T4 (P5 .002), and in OS between T2
and T3 (P5 .043) now reached statistical significance
(Fig. F33). In comparison with the 7th edition,7,8 the pro-
posed 8th edition led to a lower AIC and a higher c-index
for all endpoints (Table T33).
N Category
Only 37 patients (2%) had a lymph node larger than 6 cm
without extension into the SCF; the differences between
N3a and N2 and between N3a and N3b were statistically
insignificant for all endpoints. The overall trends were
closer to N3b, particularly in terms of D-FFS and long-
term OS (Fig. F44). Grouping with N3b without further
subclassification is hence suggested.
Replacing the N3b criterion of the SCF with the
lower neck (defined as an extension below the caudal bor-
der of the cricoid cartilage with the criteria of levels IV
and Vb of Som et al22 did not affect the N category in
1505 patients but led to upstaging from N2 to N3 in 100
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patients and downstaging from N3 to N2 in 4 patients.
The 5-year OS for those with extension to the lower neck
(70%) was similar to the 5-year OS for those with exten-
sion to the SCF (69%). Only 11 patients had a lymph
node larger than 6 cm without extension to the lower
neck.
Hence, the changes recommended for the 8th edi-
tion include changing the criterion of the SCF to the
lower neck (defined as extension below the caudal border
of the cricoid cartilage) and merging this with a
size> 6 cm as N3 criteria (Fig. 2B and Table 2). With the
proposed changes, the differences between N2 and N3 in
terms of D-FFS (P5 .010) and OS (P5 .007) and the
difference in D-FFS between N1 and N2 (P5 .042) now
reached statistical significance (Fig. 4). In comparison
with the 7th edition,7,8 although the proposed 8th edition
did not lead to an improvement in the AIC or the c-index
for N-FFS and D-FFS, it did lead to a lower AIC and
maintained the same c-index for OS (Table 3).
Stage Group
Only 63 patients (4%) presented with T1N0 disease.
There was no statistically significant difference between
stages I and II in terms of locoregional failure-free survival
(FFS; P5 .15) and only a trend toward significance in OS
(98% vs 92%, P5 .098). However, the survival curves
were clearly separated, and there was a significant differ-
ence in D-FFS (98% vs 91%, P5 .045; Fig. F55). With
adjustments for age and sex, the hazard of deaths (from all
causes) increased from 1 for stage I to 3.5 for stage II, to
6.1 for stage III, and to 11.0 for stage IVA (Table T44).
There were no significant differences between the
subgroup with T4N0-2 disease and the subgroup with
T1-4N3 disease for all endpoints, including D-FFS (78%
vs 72%, P5 .080) and OS (72% vs 70%, P5 .114).
Hence, the change recommended for the 8th edition is to
merge T4 and N3 as the criteria for advanced locoregional
disease (stage IVA) without further subclassification (Ta-
ble 2). With the proposed system, the difference in D-FFS
between stages II and III now reached statistical signifi-
cance (P5 .048; Fig. 5). In comparison with the 7th edi-
tion,7,8 the proposed 8th edition led to a lower AIC and a
higher c-index for D-FFS and OS, and it maintained the
same c-index for locoregional FFS (Table 3).
DISCUSSION
Since the milestone change in the 5th edition of the
AJCC/UICC staging system,1,2 with the development of
a customized staging system for NPC based on a combi-
nation of the strengths of Ho’s system3,4 and the AJCC/
C
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Figure 1. Overall survival: (A) T2 subgroups (different adjacent
soft tissue involvement), (B) T3 subgroups (pterygoid structures
vs skull base erosion), and (C) T4 subgroups (extensive soft tis-
sue involvement vs intracranial/cranial nerve involvement).
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UICC system, substantial support has been attained in
both endemic and nonendemic regions. As staging and
treatment methods evolve, evaluations for continual suit-
ability and improvement are important. A specific Litera-
ture Watch program has been implemented by the UICC
to capture the studies on staging systems reported in the
literature, and feedback has been obtained from an inter-
national expert panel regarding whether changes should
be considered for subsequent editions. However, the
reported studies on the evaluation of the current 7th edi-
tion of the AJCC/UICC staging system7,8 and suggestions
for further improvement are based largely on series man-
aged with past methods. Validation by more contempo-
rary series is needed.
The current study was initiated to address the con-
cerns outlined in the introduction and to explore potential
optimal changes for the coming 8th edition of the AJCC/
UICC staging system. This series of 1609 patients with a
median follow-up of 5 years, all staged withMRI and irra-
diated with IMRT at 2 major centers in Hong Kong and
mainland China, provides useful data for this validation.
Furthermore, extensive discussions by the AJCC and
UICC preparatory committee were conducted to review
the results and attain a consensus among international
multidisciplinary experts to ensure not only prognostic ac-
curacy but also optimal balance in clinical practicability
and global applicability. The main weakness of the cur-
rent study is that this is a retrospective study; further vali-
dation by prospective data will be useful.
It would be ideal if the current study could be fur-
ther validated by data from nonendemic regions; however,
most centers in nonendemic regions have only small series
of patients, and even major centers rarely capture details
of tumor extent as in the current study. Nevertheless, we
are confident that the current conclusions should be appli-
cable across countries as evidenced by the global support
for the 5th edition of the AJCC/UICC staging system, a
landmark development when we used data from Hong
Kong to combine the strengths of the 4th edition of the
AJCC/UICC staging system and Ho’s staging system to
design a customized system for NPC.
As for the T categories, the main area for improve-
ment is defining the extent of soft tissue involvement as a
T4 criterion. According to the definition stated in the 7th
edition of the AJCC cancer staging handbook, the masti-
cator space primarily consists of the muscles of mastica-
tion encompassed within the superficial layer of the deep
cervical fascia and extends from the medial and lateral
C
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Figure 2. Differences in defining criteria between the current 7th edition and the proposed 8th edition: (A) changing the extent of
soft tissue involvement as T2 and T4 criteria and (B) replacing the supraclavicular fossa (blue) with the lower neck (ie, below the cau-
dal border of cricoid cartilage; red) as N3 criteria. CS indicates carotid space; LP, lateral pterygoid muscle; M, masseter muscle; MP,
medial pterygoid muscle; PG, parotid gland; PPS, parapharyngeal space; PV, prevertebral muscle; T, temporalis muscle.
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pterygoid (MP/LP) muscles to the masseter and tempora-
lis muscles (Fig. 2A). The current study concurs with the
study by Sze et al17: the involvement of the MP/LP per se
did not lead to poor survival similar to that of patients
with extensive infiltration beyond the lateral surface of the
LP. The claim that patients with MP/LP have a poor
prognosis is likely due to the intrinsic association with
other sinister criteria. Our data showed that for patients
without other T3/T4 criteria, there were no significant
differences in OS among those with infiltration of
adjacent soft tissue, including the MP/LP, prevertebral
muscles, and parapharyngeal space alone (Fig. 1A).
Involvement of pterygoid structures should remain as T3
because the prognosis was similar to that with other skull
base bony erosions (Fig. 1B). Our data also confirmed
that patients with extensive soft tissue infiltration beyond
these structures did have a poor prognosis similar to that
of patients with intracranial extension/cranial nerve palsy
(Fig. 1C). Therefore, tumors involving these structures
should continue to be classified as T4.
Hence, the changes recommended for the 8th edition
include changing the criterion of MP/LP involvement
from T4 to T2, adding prevertebral muscle involvement as
a T2 criterion (Fig. 2), and replacing the ambiguous terms
masticator space and infratemporal fossa with a specific
description of soft tissue involvement (Table 2). This
change could help to refine the decision on the addition of
chemotherapy. Although aggressive chemotherapy with a
concurrent6 adjuvant/induction sequence is indicated for
patients with stage IV, the benefit for patients with stage II
is less certain (especially for patients irradiated with the
optimal intensity-modulated technique), and even if chem-
otherapy is used, the concurrent-alone sequence is the one
generally recommended. Hence, with more accurate prog-
nostication by downstaging pterygoid muscle involvement
to T2, these patients might be spared unnecessary chemo-
therapy if there are no other unfavorable prognostic factors.
Although the differences in D-FFS and OS between
T1 and T2 remained insignificant, the difference in
L-FFS now reached statistical significance (P5 .048). In
addition, although the differences in L-FFS and D-FFS
between T2 and T3 remained insignificant, the difference
in OS now reached statistical significance (P5 .043).
Therefore, continuing to classify them as a discrete T cate-
gory is recommended (Fig. 3).
As for the N categories, the current 7th edition of
the AJCC/UICC staging system7,8 subdivides N3 into
N3a and N3b with a nodal diameter> 6 cm (maximum
TABLE 2. Classification Criteria and Stage Grouping According to the 7th Edition and Proposed 8th Edition
of the American Joint Committee on Cancer/International Union Against Cancer Staging System
T Category
Current 7th Edition Proposed 8th Edition
T1. Nasopharynx, oropharynx, nasal fossa T1. Nasopharynx, oropharynx, nasal fossa
T2. Parapharyngeal extension T2. Parapharyngeal extension, adjacent soft tissue involvement
(medial pterygoid, lateral pterygoid, prevertebral muscles)
T3. Bony structure, paranasal sinuses T3. Bony structure (skull base, cervical vertebra), paranasal sinuses
T4. Intracranial extension, cranial nerve,
hypopharynx, orbit, infratemporal
fossa, masticator space
T4. Intracranial extension, cranial nerve, hypopharynx, orbit,
extensive soft tissue involvement (beyond the lateral surface of
the lateral pterygoid muscle, parotid gland)
N Category
Current 7th Edition Proposed 8th Edition
N0. None N0. None
N1. Retropharyngeal (regardless of laterality) N1. Retropharyngeal (regardless of laterality)
Cervical: unilateral, 6 cm, and above supraclavicular fossa Cervical: unilateral, 6 cm, and above caudal border of cricoid cartilage
N2. Cervical: bilateral, 6 cm, and above supraclavicular fossa N2. Cervical: bilateral, 6 cm, and above caudal border of cricoid cartilage
N3a.> 6 cm N3.> 6 cm and/or below caudal border of cricoid cartilage
(regardless of laterality)
N3b. In supraclavicular fossa
Stage Group
Current 7th Edition Proposed 8th Edition
I. T1N0 M0 I. T1N0 M0
II. T1N1 M0 II. T1N1 M0
T2N0-1M0 T2N0-N1M0
III. T1-2N2 M0 III. T1-2N2 M0
T3N0-2M0 T3N0-2M0
IVA. T4N0-2M0 IVA. T4 or N3M0
IVB. Any T N3M0
IVC. Any T Any N M1 IVB. Any T Any N M1
The nodal size was based on the maximum dimension in any direction.
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Figure 3. Prognostication by T category with (Left) the current 7th edition and (Right) the proposed 8th edition: (A) local failure-
free rate, (B) distant failure-free rate, and (C) overall survival.
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Figure 4. Prognostication by N category with (Left) the current 7th edition and (Right) the proposed 8th edition: (A) nodal
failure-free rate, (B) distant failure-free rate, and (C) overall survival.
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Figure 5. Prognostication by stage group with (Left) the current 7th edition and (Right) the proposed 8th edition: (A) locore-
gional failure-free rate, (B) distant failure-free rate, and (C) overall survival.
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dimension) and extension into the SCF3 as respective cri-
teria. The significance of the size criterion was difficult to
evaluate because few patients had a large lymph node
without reaching the SCF3 (n5 35) or the lower neck
(n5 11). Because the outcome pattern of N3a was similar
to that of N3b, particularly for long-term D-FFS and OS
(Fig. 4), continuing to use this as an N3 criterion was sup-
ported. However, in agreement with the study by Lee
et al,28 further subclassification could be discontinued as
the number of patients was too few for meaningful
impact.
The feasibility of replacing the SCF3 with the lower
neck (defined as extension below the caudal border of the
cricoid cartilage22; ie, levels IV and Vb; Fig. 2B) without
affecting the prognostic significance was first reported by
Ng et al23 in 2007. This was adopted as the criterion for
N3 in the Chinese system (2008 version).24-27 There is lit-
tle controversy that this leads to easier and more reproduc-
ible demarcation by imaging instead of clinical palpation.
Although the current data showed that this did not lead to
an improvement in the AIC or the c-index for N-FFS and
D-FFS, the c-index for OS was maintained (Table 3). To-
gether with merging with nodes> 6 cm (maximum
dimension), differences in D-FFS and OS were significant
between all adjacent N categories in the proposed 8th
edition.
As for the stage grouping scheme, the current article
concurs with the study by Lee et al28: subclassification
into IVA and IVB was unnecessary because the OS of
patients with T4N0-2 disease was similar to the OS of
those with T1-4N3 disease (72% vs 70% at 5 years,
P5 .114). Hence, all T4 and N3 can be merged into 1
substage (IVA) for advanced locoregional disease. How-
ever, further simplification by the merging of stages I and
II was not recommended. Even though only 4% of
patients presented with T1N0 disease and there was no
significant difference between stages I and II in locore-
gional FFS (P5 .15) or OS (98% vs 92%, P5 .098), the
difference in D-FFS was significant (98% vs 91%,
P5 .045). Because of the concern that stage II patients
might benefit from the addition of chemotherapy, keep-
ing stages I and II separate is recommended.
NPC has a highly skewed global distribution, with
80% of the global burden in Asian countries. According
to the statistics from GLOBOCAN in 2012,38 the total
number of new cases of NPC in the world was 86,691,
and 33,198 of these cases (38%) were registered in China.
It is understandable that centers from China take great
interest in developing the best possible staging system
for this cancer. Although most countries adopt the
AJCC/UICC system, China is the only country that still
commonly uses a different system. A comparison of the 2
systems by Pan et al25 showed that the prognostic value of
the T category in the 7th edition of the AJCC/UICC stag-
ing system7,8 was superior, whereas the prognostic value
of the N category in the 2008 Chinese edition was supe-
rior; for the prediction of OS by stage group, the 2 systems
were comparable. The study by OuYang et al26 also sup-
ported the superiority of the N category in the Chinese
2008 edition in the IMRT era. Our current analyses sup-
port merging the strengths of the 2 systems.
In summary, the proposed 8th edition adopts the
easily reproducible definition of the lower neck as an N3
criterion, clarifies the appropriate T2 criteria, avoids am-
biguous terms, and discontinues subclassifications that
have little impact. These changes will lead to a better dis-
tinction of hazards between adjacent stages/categories
(Figs. 2–4) and improvements in both the AIC and the c-
index by the proposed T category for all endpoints and by
the proposed stage group for D-FFS and OS. This repre-
sents a concerted effort by endemic centers together with
multidisciplinary international experts to develop the
optimal staging system and work toward global unity.
After the optimization of the fundamental TNM
staging system, further refinement of prognostication by
additional independent factors will be useful for guiding
treatment and cost-effective use of health care resources.
There are increasing data showing that tumor volume is
one of the most promising factors, but this is not incorpo-
rated into the current TNM system because the measure-
ment of this criterion is not globally available and
consensus on the cutoff value has yet to be attained. Fur-
ther studies to develop a nomogram with the incorpora-
tion of additional prognostic factors are now ongoing in
an attempt to work toward a personalized treatment strat-
egy tailored to an individual’s risk pattern.
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0000 Proposal for the 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of
Intensity-Modulated Radiotherapy
Jian Ji Pan, Wai Tong Ng, Jing Feng Zong, Lucy L. K. Chan, Brian O’Sullivan, Shao Jun Lin, Henry C. K. Sze, Yun
Bin Chen, Horace C. W. Choi, Qiao Juan Guo, Wai Kuen Kan, You Ping Xiao, Xu Wei, Quynh Thu Le, Christine M.
Glastonbury, A. Dimitrios Colevas, Randal S. Weber, Jatin P. Shah, and Anne W. M. Lee
On the basis of a literature review and analyses of 1609 patients with nasopharyngeal cancer staged and treated with
contemporary methods, the following changes will be recommended for the 8th edition of the American Joint Committee
on Cancer/International Union Against Cancer staging system: changing pterygoid muscle involvement from T4 to T2,
adding prevertebral muscle involvement as T2, replacing the supraclavicular fossa with the lower neck (extension below
the caudal border of the cricoid cartilage) and merging this with a maximum nodal diameter> 6 cm as N3, and merging
T4 and N3 as stage IVA criteria. These changes will lead not only to a better distinction of hazards between adjacent
stages/categories but also to an optimal balance in clinical practicability and global applicability.
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